Amgen (AMGN) Stock Forecast & Price Target

$321.03

-1.18 (-0.37%)

(As of 03:04 PM ET)

Amgen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
1

Hold
11

Buy
12

Based on 24 Wall Street analysts who have issued ratings for Amgen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 11 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for AMGN.

Consensus Price Target

$325.55
2.41% Upside

According to the 24 analysts' twelve-month price targets for Amgen, the average price target is $325.55. The highest price target for AMGN is $405.00, while the lowest price target for AMGN is $215.00. The average price target represents a forecasted upside of 2.41% from the current price of $321.03.

Get the Latest News and Ratings for AMGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Amgen and its competitors.

AMGN Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$325.55	$326.89	$307.35	$266.69
Forecasted Upside	2.41% Upside	-2.08% Downside	-0.66% Downside	0.14% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Next Week Elon Could Trigger a Boom in this Sub-$3 Stock (Ad)

Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world…

Click here to see the details and save your seat.

AMGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amgen Stock vs. The Competition

Type	Amgen	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	2.31% Upside	831.35% Upside	6.78% Upside
News Sentiment Rating	Positive News See Recent AMGN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/27/2024	Cantor Fitzgerald 3 of 5 stars	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$405.00	+26.92%
9/26/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$362.00 ➝ $362.00	+14.85%
9/25/2024	Robert W. Baird 2 of 5 stars		Reiterated Rating	Underperform ➝ Underperform	$215.00 ➝ $215.00	-31.92%
9/16/2024	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$360.00 ➝ $381.00	+21.92%
8/7/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$325.00 ➝ $330.00	+6.40%
Get the Latest News and Ratings for AMGN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.
8/7/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$310.00 ➝ $305.00	-1.66%
8/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$380.00 ➝ $380.00	+22.53%
8/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$375.00 ➝ $380.00	+22.79%
8/7/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$320.00 ➝ $335.00	+1.84%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$310.00 ➝ $303.00	-6.67%
6/27/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$300.00 ➝ $340.00	+8.87%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$223.00 ➝ $235.00	-23.53%
5/3/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$284.00 ➝ $307.00	-1.65%
5/3/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$336.00 ➝ $355.00	+12.91%
5/3/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$230.00 ➝ $300.00	+7.76%
5/3/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/12/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$320.00	+19.35%
3/28/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
2/7/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/7/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$313.00 ➝ $350.00	+10.73%
2/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$324.00 ➝ $318.00	+0.61%
12/21/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$264.00 ➝ $320.00	+16.29%
10/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$270.00	-3.69%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$320.00	+25.98%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$220.00 ➝ $200.00	-10.66%
4/28/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$293.00 ➝ $288.00	+19.83%
2/2/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$282.00 ➝ $267.00	+8.36%
2/1/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$307.00 ➝ $289.00	+14.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:28 PM ET.

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 30, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

Amgen
Bull Case

Here are some ways that investors could benefit from investing in Amgen Inc.:

Amgen's stock price has shown resilience, currently trading at $312.86, with a 52-week high of $346.85, indicating potential for growth.
Amgen has a strong track record of dividend payments, offering a dividend yield of 2.68%, providing investors with a steady income stream.
Analysts have given Amgen a consensus rating of "Moderate Buy" with an average target price of $321.37, suggesting positive sentiment towards the stock.
Amgen's recent earnings report showed a revenue increase of 20.1% compared to the same quarter last year, indicating strong financial performance.
Several investment firms have raised their price targets on Amgen, with positive ratings and outlooks, signaling confidence in the company's future growth potential.

Amgen
Bear Case

Investors should be bearish about investing in Amgen Inc. for these reasons:

Amgen's stock price experienced a 5.5% decline recently, reaching $312.86, which may indicate short-term volatility and potential risks.
Amgen's P/E ratio of 44.69 and PEG ratio of 2.98 suggest that the stock may be overvalued compared to industry peers, posing a risk for investors.
There is a high debt-to-equity ratio of 9.64 for Amgen, which could lead to increased financial leverage and potential instability in the company's financial position.
While Amgen has a strong dividend payout, the dividend payout ratio of 128.57% indicates that the company is paying out more in dividends than it is earning, which may not be sustainable in the long term.
Despite positive analyst ratings, there is a sell rating on Amgen, suggesting some analysts have concerns about the company's future performance or market conditions.

AMGN Forecast - Frequently Asked Questions

: According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Amgen is $325.55, with a high forecast of $405.00 and a low forecast of $215.00.
: 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There is currently 1 sell rating, 11 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMGN shares.
: According to analysts, Amgen's stock has a predicted upside of 1.41% based on their 12-month stock forecasts.
: Over the previous 90 days, Amgen's stock had 1 upgrade and 1 downgrade by analysts.
: Amgen has been rated by research analysts at Bank of America, Cantor Fitzgerald, Dbs Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, Morgan Stanley, Oppenheimer, Robert W. Baird, Royal Bank of Canada, TD Cowen, and Wells Fargo & Company in the past 90 days.
: Analysts like Amgen less than other "medical" companies. The consensus rating score for Amgen is 2.50 while the average consensus rating score for "medical" companies is 2.78. Learn more on how AMGN compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Next Week Elon Could Trigger a Boom in this Sub-$3 Stock (Ad)

Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world…

Click here to see the details and save your seat.

This page (NASDAQ:AMGN) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners